3',4'-Methylenedioxy-α-pyrrolidinopropiophenone

3',4'-Methylenedioxy-α-pyrrolidinopropiophenone

Clinical data
Routes of administration	By mouth, insufflation, vaporization, IV, rectal, sublingual
Legal status
Legal status	DE: Anlage I (Authorized scientific use only) UK: Class B
Pharmacokinetic data
Metabolism	Hepatic[1][2]
Excretion	Primarily urine (renal)
Identifiers
IUPAC name (RS)-1-(3,4-methylenedioxyphenyl)-2-(1-pyrrolidinyl)-1-propanone
CAS Number	783241-66-7
PubChem CID	6430845
ChemSpider	4936183
UNII	83IP4LIH8E
CompTox Dashboard (EPA)	DTXSID001024625
Chemical and physical data
Formula	C14H17NO3
Molar mass	247.294 g·mol−1
3D model (JSmol)	Interactive image
Chirality	Racemic mixture
SMILES c3c1OCOc1ccc3C(=O)C(C)N2CCCC2
InChI InChI=1S/C14H17NO3/c1-10(15-6-2-3-7-15)14(16)11-4-5-12-13(8-11)18-9-17-12/h4-5,8,10H,2-3,6-7,9H2,1H3 Key:NIYQOTCYXGXMPI-UHFFFAOYSA-N

3',4'-Methylenedioxy-α-pyrrolidinopropiophenone (MDPPP) is a stimulant designer drug. It was sold in Germany in the late 1990s and early 2000s as an ingredient in imitation ecstasy (MDMA) pills.^[3] It shares a similar chemical structure with α-PPP and MDPV,^[4][1][2] and has been shown to have reinforcing effects in rats.^[5]

1. ^ ^{a b} Staack RF, Maurer HH (June 2005). "Metabolism of designer drugs of abuse". Current Drug Metabolism. 6 (3): 259–74. doi:10.2174/1389200054021825. PMID 15975043.
2. ^ ^{a b c} Springer D, Staack RF, Paul LD, Kraemer T, Maurer HH (March 2005). "Identification of cytochrome P450 enzymes involved in the metabolism of 3',4'-methylenedioxy-alpha-pyrrolidinopropiophenone (MDPPP), a designer drug, in human liver microsomes". Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 35 (3): 227–37. doi:10.1080/00498250400028239. PMID 16019948. S2CID 28207896.
3. ^ Springer D, Fritschi G, Maurer HH (August 2003). "Metabolism and toxicological detection of the new designer drug 3',4'-methylenedioxy-alpha-pyrrolidinopropiophenone studied in urine using gas chromatography-mass spectrometry". Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 793 (2): 377–88. doi:10.1016/S1570-0232(03)00350-7. PMID 12906913.
4. ^ Maurer HH, Kraemer T, Springer D, Staack RF (April 2004). "Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis". Therapeutic Drug Monitoring. 26 (2): 127–31. doi:10.1097/00007691-200404000-00007. PMID 15228152. S2CID 9255084.
5. ^ Gannon BM, Galindo KI, Mesmin MP, Sulima A, Rice KC, Collins GT (May 2018). "Relative reinforcing effects of second-generation synthetic cathinones: Acquisition of self-administration and fixed ratio dose-response curves in rats". Neuropharmacology. 134 (Pt A): 28–35. doi:10.1016/j.neuropharm.2017.08.018. PMC 5809320. PMID 28811192.
6. ^ "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Archived from the original on 1 October 2015. Retrieved 1 October 2015.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

• v
• t
• e